Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CCR4-NOT transcription complex subunit 9 (CNOT9)
- Target
- CNOT9
- Molecular classification
- Transcriptional cofactor (component of multiprotein complex), Other (core subunit of CCR4-NOT deadenylation complex, not a classical receptor, enzyme, or channel)[2][3][4]
01
Overview
CCR4-NOT transcription complex subunit 9 (CNOT9) is a highly conserved core component of the CCR4-NOT complex, which is the major cellular mRNA deadenylase complex in eukaryotes. CNOT9 functions as a transcriptional cofactor and is crucial for processes including mRNA deadenylation, degradation, translational repression, miRNA-mediated gene silencing, and general transcriptional regulation. It interacts with other proteins such as CNOT1 and provides structural binding sites for proteins mediating these regulatory functions. CNOT9 participates in retinoic acid-regulated cell differentiation and development, and while not a classic drug target, has disease relevance as a cancer/testis antigen and as a component implicated in certain developmental disorders[1][2][3][4][5][6].
- Other names
- RCD1RQCD1Rcd-1RCD1+CT129CAF40Cell differentiation protein RQCD1 homologCancer/testis antigen 129Cell differentiation protein RCD1 homologProtein involved in sexual development
02
Mechanism of action
Not applicable\nNo direct drug mechanisms have been reported for agents targeting CNOT9, as it is not a classical drug target[3].
03
Biological functions
mRNA deadenylation and decayTranscriptional regulation (initiation and elongation)Translational repressionmiRNA-mediated gene silencingRegulation of cell differentiation and development[1][2][3][4][6]
04
Disease associations
Cancer (notably involvement as a cancer/testis antigen)Developmental disorders (including reported associations with developmental dysplasia of the hip and epilepsy)[3][5]Other (broad roles in mRNA metabolism may implicate the complex in additional disease states, though CNOT9-specific associations are limited)
05
Safety considerations
Not established\nNo known safety concerns specific to therapeutic targeting of CNOT9, as it is not currently a drug target. Disruption of CCR4-NOT complex integrity could affect global gene expression regulation[4][6].
06
Biomarkers
Cancer/testis antigen 129 (CT129) status (potentially in some cancers; CNOT9/RCD1 expression may be investigated, but no established role as a biomarker in clinical use)[5]
Beyond the preview
Go deeper on CCR4-NOT transcription complex subunit 9 (CNOT9).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CCR4-NOT transcription complex subunit 9 (CNOT9).